Characterization of Endocannabinoid and Endogenous Opioid Levels in Adolescents With Cannabis Use Disorder
| Trial ID | NCT05396638 |
| Status | Recruiting |
| Condition | Cannabis Use |
| Intervention | Contingency Management |
This trial addresses a critical gap in understanding how cannabis use disorder affects developing neurochemical systems in adolescents. Identifying biomarkers that predict relapse could transform how we approach treatment and monitoring in this vulnerable population.
This observational study is recruiting adolescents with cannabis use disorder to characterize endocannabinoid and endogenous opioid system changes through biomarker analysis. The trial uses contingency management as an intervention while measuring neurochemical markers to identify patterns that may distinguish youth likely to relapse from those who maintain sobriety. Participants undergo systematic assessment of endocannabinoid and opioid system function to establish baseline patterns and track changes over time.
“If this research identifies reliable biomarkers for relapse risk, we could move toward personalized treatment approaches for adolescent cannabis use disorder. Having objective measures to guide intervention intensity and predict outcomes would represent a significant advance in adolescent addiction medicine.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
What is the NCT05396638 study about, and is it recruiting?
It is an observational study, currently listed as recruiting, of adolescents with cannabis use disorder. Its goal is to characterize changes in the endocannabinoid and endogenous opioid systems through biomarker analysis.
What does taking part in this adolescent cannabis study involve?
Participants receive contingency management, which is listed as the study’s intervention, while researchers measure neurochemical markers. They undergo systematic assessment of endocannabinoid and opioid system function to establish baseline patterns and then track how these patterns change over time.
Why could relapse biomarkers matter for teens with cannabis use disorder?
The study aims to identify neurochemical patterns that may distinguish youth likely to relapse from those who maintain sobriety. The article notes a critical gap in understanding how cannabis use disorder affects developing neurochemical systems in adolescents, and it states that biomarkers predicting relapse could transform how treatment and monitoring are approached in this vulnerable population.
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
